Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.) ; 49(8): [e102044], nov.-dic. 2023. ilus
Article de Espagnol | IBECS | ID: ibc-228030

RÉSUMÉ

Los determinantes sociales de la salud influyen significativamente en el desarrollo y en la progresión de enfermedades crónicas como la diabetes tipo2 (DM2). Este artículo examina los determinantes sociales clave, incluidos la educación, la estabilidad económica, el vecindario, así como la procedencia, la raza o la religión, que afectan a las personas con DM2. También se explora el papel del género como determinante social, enfatizando la necesidad de consideraciones específicas de género en la gestión y en la investigación de la DM2. Además, se analiza el impacto de la pobreza en los resultados de salud, destacando la relación bidireccional entre pobreza y enfermedad. Las medidas integrales que abordan estos determinantes son cruciales para mejorar la salud y el bienestar de las personas con DM2. Abordar las desigualdades sociales a través de intervenciones específicas puede contribuir a mejores resultados de tratamiento y a una atención médica equitativa (AU)


Social determinants of health significantly influence the development and progression of chronic diseases such as type2 diabetes (T2DM). This article examines key social determinants including education, economic stability, neighborhood, and factors such as ethnicity, race, or religion that impact individuals with T2DM. The role of gender as a social determinant is also explored, emphasizing the need for gender-specific considerations in T2DM management and research. Additionally, the impact of poverty on health outcomes is analyzed, highlighting the bidirectional relationship between poverty and disease. Comprehensive measures addressing these determinants are crucial to improving the health and well-being of individuals with T2DM. Addressing social inequalities through targeted interventions can contribute to better treatment outcomes and equitable healthcare (AU)


Sujet(s)
Humains , Déterminants sociaux de la santé , Vulnérabilité en Santé , Diabète
2.
Semergen ; 49(8): 102044, 2023.
Article de Espagnol | MEDLINE | ID: mdl-37481793

RÉSUMÉ

Social determinants of health significantly influence the development and progression of chronic diseases such as type2 diabetes (T2DM). This article examines key social determinants including education, economic stability, neighborhood, and factors such as ethnicity, race, or religion that impact individuals with T2DM. The role of gender as a social determinant is also explored, emphasizing the need for gender-specific considerations in T2DM management and research. Additionally, the impact of poverty on health outcomes is analyzed, highlighting the bidirectional relationship between poverty and disease. Comprehensive measures addressing these determinants are crucial to improving the health and well-being of individuals with T2DM. Addressing social inequalities through targeted interventions can contribute to better treatment outcomes and equitable healthcare.


Sujet(s)
Diabète de type 2 , Déterminants sociaux de la santé , Humains , Facteurs socioéconomiques , Niveau d'instruction , Pauvreté
3.
Semergen ; 46(6): 415-424, 2020 Sep.
Article de Espagnol | MEDLINE | ID: mdl-32094051

RÉSUMÉ

The prevalence of type 2 diabetes (DM2) diagnosed in childhood and adolescence is currently increasing, and is characterised by a rapidly progressive decline in beta-cells and insulin resistance. Physical inactivity and obesity are the main risk factors for its development. Diagnostic criteria are similar to those used in adults, although HbA1c as a diagnostic method is questioned. Diabetes-related complications are more aggressive than in adults. Diabetic nephropathy is the most frequent complication in the young population and macrovascular complications appear early, leading to high mortality rates. Healthy lifestyles are the basis of the treatment, and metformin, insulin and liraglutide (approved by FDA for its use in the United States) are the pharmacological options indicated in this population. It is important to establish models of health care transition from paediatric to adult care to ensure continuity of care and avoid patient disengagements.


Sujet(s)
Diabète de type 2 , Transition aux soins pour adultes , Adolescent , Diabète de type 2/thérapie , Humains , Insuline , Metformine , Soins de santé primaires , États-Unis , Jeune adulte
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE